28,501 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by Aquatic Capital Management LLC

Aquatic Capital Management LLC acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,501 shares of the company's stock, valued at approximately $2,333,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Vaxcyte during the 3rd quarter worth about $355,000. Franklin Resources Inc. lifted its position in Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after buying an additional 324,560 shares in the last quarter. Lord Abbett & CO. LLC raised its position in shares of Vaxcyte by 26.9% during the 3rd quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company's stock valued at $35,701,000 after buying an additional 66,183 shares during the period. Principal Financial Group Inc. increased its position in shares of Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock valued at $6,022,000 after acquiring an additional 34,287 shares during the last quarter. Finally, Everence Capital Management Inc. purchased a new position in Vaxcyte during the 4th quarter valued at about $301,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. The Goldman Sachs Group lowered their target price on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating for the company. Bank of America cut their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Up 0.4 %

PCVX traded up $0.15 during trading hours on Friday, hitting $35.39. 1,940,078 shares of the company's stock were exchanged, compared to its average volume of 1,263,735. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The stock's 50-day moving average is $50.92 and its two-hundred day moving average is $77.08. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of -7.69 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 24,000 shares of company stock worth $1,946,720 in the last ninety days. 3.10% of the stock is owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.